ArticleCancer medicine2020
Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer:A population-based study.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.BMC urology · 2023Trial
- A Clinically Practical Nomogram for Predicting Survival in Elderly Patients (≥ 65 Years) With Bladder Urothelial Carcinoma: A Study Based on SEER Database and External Validation.Cancer reports (Hoboken, N.J.) · 2025Article
- Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.BMC cancer · 2025Article
- Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Nomogram for predicting all-cause mortality and cancer-specific mortality after TURBT for non-muscle-invasive bladder cancer.Scientific reports · 2024Article
- A Novel Decision Tree Model for Predicting the Cancer-Specific Survival of Patients with Bladder Cancer Treated with Radical Cystectomy.Journal of clinical medicine · 2024Article
- Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study.European journal of medical research · 2023Article
- Surveillance of prognostic risk factors in patients with SCCB using artificial intelligence: a retrospective study.Scientific reports · 2023Article
- Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort.Frontiers in oncology · 2023Article
- A Prognostic Nomogram Based on Log Odds of Positive Lymph Nodes to Predict Overall Survival for Non-Metastatic Bladder Cancer Patients after Radical Cystectomy.Current oncology (Toronto, Ont.) · 2022Article
- Mortality Trends Related to Bladder Cancer in Spain, 1999-2018.Journal of clinical medicine · 2022Article
- A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Muscle-Invasive Bladder Cancer Patients after Partial Cystectomy.Journal of oncology · 2022Article
- Development and Validation of a Prognostic Nomogram for Predicting Overall Survival for T1 High-Grade Patients After Radical Cystectomy: A Study Based on SEER.International journal of general medicine · 2022Article
- Competitive Risk Model for Specific Mortality Prediction in Patients with Bladder Cancer: A Population-Based Cohort Study with Machine Learning.Journal of oncology · 2022Article
- Predictive Value of the Log Odds of Negative Lymph Nodes/T Stage as a Novel Prognostic Factor in Bladder Cancer Patients After Radical Cystectomy.Frontiers in oncology · 2022Article
- Development and Validation of a Prognostic Nomogram for Predicting Cancer-Specific Survival in Patients With Lymph Node Positive Bladder Cancer: A Study Based on SEER Database.Frontiers in oncology · 2022Article
- Article
- Development and Validation of a Prognostic Model for Predicting Overall Survival in Patients With Bladder Cancer: A SEER-Based Study.Frontiers in oncology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo establish a prognostic model to estimate the cancer-specific survival (CSS) for urothelial carcinoma of bladder (UCB) patients after radical cystectomy (RC).
methodsA total of 8650 candidates (2004-2011) obtained from the Surveillance, Epidemiology, and End Results (SEER) database were randomly split into development cohort (n = 4323) and validation cohort (n = 4327). We performed Cox regression analysis to identify prognostic factors and Kaplan-Meier analysis to assess survival outcome. A nomogram predicting CSS was constructed. Its performance was validated by calibration curves, the receiver operating characteristic (ROC) curves, concordance index (C-index), decision curve analysis (DCA), the net reclassification improvement (NRI), and the integrated discrimination improvement (IDI).
resultsThe nomogram incorporated marital status, T stage, N stage, tumor size, and chemotherapy. In validation cohort, C-index of the nomogram was 0.707. AUC of the nomogram and AJCC stage were 0.767 versus 0.674. Calibration plots for 3- and 5-year CSS displayed good concordance. DCA curves of the nomogram exhibited larger benefits than the AJCC stage. The NRI and IDI indicated the nomogram outperformed AJCC stage.
conclusionsWe have established a prognostic nomogram with improved discriminative ability and clinical benefits for UCB patients after RC. The nomogram alongside an easy access web tool may assist clinicians in optimizing the postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.